Milestone achieved in Scribe and Lilly’s ongoing collaboration to develop in vivo CRISPR-based therapeutics for neurological and neuromuscular diseasesAchievement validates Scribe’s technologies and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results